Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Protalex, Inc. company was founded in 1999 and is headquartered in New Hope, Pennsylvania. Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. Protalex company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100, is a purified form of the Staphylococcal bacterial protein known as Protein A that has the ability to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are key cells mediating inflammation in certain autoimmune diseases.

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The company's lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.

Hycor Biomedical makes medical diagnostic products and sells them in the US and abroad. Hycor's KOVA urinalysis system, which enables labs to perform uniform microscopic analyses of urine specimens, is used in applications including personnel safety and pregnancy testing. Hycor company also produces allergy diagnosis products and kits for detecting rheumatoid arthritis and other autoimmune diseases. Its products are sold by distributors and the company's sales force. Hycor Biomedical is a subsidiary of life sciences company Agilent.

Fibrocell Science, Inc., a biotechnology company, focuses on developing regenerative fibroblast cells for aesthetic, medical, and scientific applications. The company is developing Azfibrocel-T, an investigational autologous cell therapy to treat nasolabial fold wrinkles. It was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. The company is based in Exton, Pennsylvania.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. Medical Nutrition company's customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

ZIOPHARM Oncology, Inc. company was founded in 2003 and is based in New York, New York. ZIOPHARM Oncology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The company’s products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the company's development and commercialization of oncology therapeutics.

ProMetic was founded in 1994. The scientists at ProMetic Life Sciences are meticulous about proteins. The biotech company develops protein technologies for pharmaceutical, diagnostic, and blood and plasma product development. ProMetic's Protein Technologies division licenses its technologies to companies around the globe, who then make their own products. The company's Therapeutics division conducts proprietary drug development programs for blood disease and cancer therapeutics. The company has collaborative agreements with pharmaceutical companies and health organizations such as Abraxis BioScience, Merck Serono, and The American Red Cross.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.